|
Studies included in the analysis |
|||||||||||
| Study |
Duration (weeks) |
No. in ITT (PR) populations |
Main eligibility criteria |
COPD medication allowed during the study |
|||||||
|
|
|||||||||||
| Salmeterol |
Placebo |
Definition |
Age (yrs) |
FEV1 (% predicted % absolute value) |
FEV1/FVC |
OCS |
ICS |
Antichol. |
MX |
||
|
|
|||||||||||
| van Noord |
12 |
49 (40) |
50 (44) |
ATS |
40–75 |
≤65% & ≥ 0.75L |
≤60% |
Yes |
≤ 1 mg/day FP* |
No |
Yes |
| Rennard |
12 |
131 (84) |
133 (85) |
ATS |
≥35 |
≤ 65% & > 0.7L or ≥ 40% & <0.7L |
≤70% |
≤ 10 mg prednisolone* |
Yes |
No |
No |
| Mahler |
12 |
135 (78) |
143 (90) |
ATS |
≥35 |
≤65% & >0.7L or ≥ 40% & <0.7L |
≤70% |
≤10 mg prednisolone* |
Yes |
No |
No |
| Boyd |
16 |
228 (221) |
227 (215) |
ERS |
40–75 |
≤70% & >0.6L |
≤60% |
Yes |
Yes |
Yes |
Yes |
| Mahler |
24 |
164 (105) |
185 (130) |
ATS |
≥40 |
<65% & >0.7L or >40% & ≤0.7L |
≤70% |
No |
No |
No |
Yes |
| Hanania |
24 |
176 (112) |
185 (118) |
ATS |
≥40 |
<65% & > 0.7L or >40% & ≤0.7L |
≤70% |
No |
No |
No |
Yes |
| Chapman |
24 |
201 (173) |
206 (171) |
ERS |
≥40 |
≤85% |
≤70% |
Yes |
Yes |
Yes |
Yes |
| Calverley |
52 |
372 (371) |
361 (359) |
ERS |
40–79 |
≥25%–≤70% |
≤70% |
Exacerbations |
No |
Yes |
Yes |
| Stockley |
52 |
316 (292) |
318 (304) |
ERS |
≥40 |
<70% |
Not stated |
Exacerbations |
≤1 mg/day FP* |
Yes |
Yes |
| Pooled |
1772 (1476) |
1808 (1516) |
|||||||||
|
* or equivalent; ATS: American Thoracic Society; ERS: European Respiratory Society; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; OCS: oral corticosteroids; ICS: inhaled corticosteroids; Antichol: anticholinergics; MX: methylxanthines. FP: fluticasone propionate | |||||||||||
Stockley et al. Respiratory Research 2006 7:147 doi:10.1186/1465-9921-7-147 |
|||||||||||